HYDRA

Hydra Biotech AG is a Swiss biotechnology company developing non-viral gene therapy for primary mitochondrial disease.

Primary mitochondrial diseases affect thousands of patients across Europe and the United States. There is no approved disease-modifying therapy, and existing gene-therapy approaches reach only a fraction of the underlying genetic causes.

We are developing a delivery platform capable of carrying macromolecular cargo to the mitochondrion, addressing disease at its genetic source.

Philip L. A. Hahn, CFA

Philip holds an M.A. in Biotechnology from Columbia University’s Department of Biological Sciences, with post-baccalaureate pre-medical training at New York University, and a B.S. from Georgetown University’s School of Foreign Service.

He was previously Chairman of Hahn Family Wines, which he restructured and grew into the twelfth-largest independent winery in the United States before its sale to E&J Gallo. He is the founder of Hydra Cross Asset Fund.